Arabs represent about 5% of the world population and are massively underrepresented in genomic studies worldwide, yet minimal efforts have been made to date to understand clinical utility of polygenic scores in this group.
Explore This Lab
About Knipe Laboratory
Repetitive injury to the lung is believed to initiate many chronic lung diseases, including pulmonary fibrosis. The lung’s ability to repair normally depends on functional cellular processes involving epithelial cells, endothelial cells, immune cells, and fibroblasts. Ineffective repair leads to persistent tissue damage and fibrotic scarring. One example of inadequate repair in patients with pulmonary fibrosis is the failure of type 2 alveolar epithelial cells (AEC) to differentiate into type 1 AECs.
The Knipe Laboratory at Massachusetts General Hospital, led by Rachel Knipe, MD, is interested in understanding the mechanisms that lead to ineffective repair and fibrosis, focusing on the role of endothelial dysfunction in this process. We believe that persistent endothelial dysfunction activates fibroblasts and prevents epithelial regeneration after injury, thereby tipping the balance in the lung toward fibrosis rather than repair. We are interested in idiopathic pulmonary fibrosis (IPF) and fibrosis that occurs in the context of systemic diseases, such as connective tissue disease (CTD), and after viral infections, such as influenza or COVID-19 infections.
Endothelial cells are important for many tissue functions, with one primary role being modulating vascular permeability. The Knipe laboratory is interested in signaling pathways that regulate vascular permeability, including Rho kinase (ROCK) and sphingosine-1-phosphate (S1P). Both pathways induce significant cytoskeletal changes that influence endothelial barrier function. In addition, they mediate downstream signaling that controls migration, proliferation, and survival. The Knipe Lab has shown vital links between these signaling pathways and fibrotic outcomes in both bleomycin- and influenza-induced animal models of pulmonary fibrosis.
- Loss of endothelial S1PR1 drives post-influenza pulmonary fibrosis
- Activation of endothelial ROCK2 drives pulmonary fibrosis through increased vascular permeability
- Defining histologic and transcriptional changes in the lung endothelium that contribute to progressive pulmonary fibrosis
Awards and Recognitions
Rachel Knipe, MD, is supported by a Career Development Award from the NIH NHLBI (K08), awarded in 2018, and an NIH NHLBI R03, awarded in 2022. In 2021, she received the Eleanor Shore Fellowship Award from Harvard Medical School and Mass General Department of Medicine, and a Boehringer Ingelheim Discovery ILD Award. In 2022, she received the Jo Rae Wright Award from the American Thoracic Society Respiratory Cell and Molecular Biology Assembly.
- Rachel Knipe, MD (PI)
- Patricia Brazee, PhD (Instructor)
- Shatruhan Rajput, PhD (Post-doctoral fellow)
- Trong Nguyen, BS (Lab Manager)
- Roxene Clarke (Mouse Colony Manager)
- Katharine Ference, BS (Technician)
How to Apply
We are always looking for postdoctoral fellows interested in research at the interface of vascular biology and pulmonary fibrosis. Interested applicants should email Dr. Rachel Knipe with their detailed curriculum vitae and a cover letter describing relevant training and research experience.
Related News and Articles
- Oct | 16 | 2023
Florez now oversees the largest clinical and research department at Mass General, with 10 clinical divisions, seven research centers/units, and 19 training programs comprising over 1,000 faculty members, 900 trainees and 100 medical practices.
- Sep | 20 | 2023
Research Spotlight: Population Health Impact, Cost-Effectiveness, and Affordability of Community-Based HIV Treatment and Monitoring in South Africa: A Health Economics Modelling Study
A modeling study projects that by 2060, community-based HIV treatment and monitoring averts 28% of HIV-related deaths and 28% of new infections.
- Press Release
- Aug | 10 | 2023
Transplant Recipients Experience Limited Protection With Primary COVID-19 Vaccination Series, but Third Dose Boosts Response
For lung and heart transplant recipients, vaccine doses beyond the third dose are likely important for maintaining immunity.
- Press Release
- Aug | 7 | 2023
Method will help clinicians monitor and treat critically ill patients.
- Press Release
- Jul | 24 | 2023
The NLRP11 protein is a previously missing link that could advance the study of infections.